
RNTX Stock Forecast & Price Target
RNTX Analyst Ratings
Bulls say
Rein Therapeutics Inc is positioned favorably due to its focus on developing therapies for orphan pulmonary and fibrosis indications, with two Phase 2-ready clinical assets that address unmet medical needs. The company's clinical trials have shown promising results, particularly with LTI-03, which demonstrated increased sRAGE levels, indicating potential efficacy. Overall, the stock presents a favorable risk-reward opportunity, especially if the company successfully extends its cash runway, supported by a best-in-class pipeline targeting significant market opportunities currently lacking in effective treatment options.
Bears say
Rein Therapeutics Inc's stock has experienced a significant decline of 50% year to date in 2025, which starkly contrasts with the 3.5% increase observed in the XBI index. This deterioration in stock performance is largely attributed to the company's decision to pause enrollments in the U.S. for its clinical trials, creating heightened investor uncertainty regarding future progress and revenue potential. Furthermore, concerning biomarker data indicates that lower sRAGE levels are linked to poor survival outcomes in patients with Idiopathic Pulmonary Fibrosis, raising questions about the efficacy and viability of the company's therapeutic candidates in a competitive market.
This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNTX Analyst Forecast & Price Prediction
Start investing in RNTX
Order type
Buy in
Order amount
Est. shares
0 shares